Invivyd, Inc.
IVVDHealthcareNASDAQBiotechnology · Last scanned Sep 7, 2026
Scan Results
Daily timeframeInvivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in. The company carries a $243.5M market cap, placing it firmly in the micro-cap category. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.
Market Cap
$243.5M
Beta
0.81
P/E (TTM)
—
P/E (Fwd)
-1.50
EPS (TTM)
$-0.31
EPS (Fwd)
$-0.55
ROE
-95.9%
ROA
-45.7%
Cash
$160.1M
Total Debt
$8.4M
Free CF
-$70.0M
52W Change
-28.8%
Annual Financials
Cash vs Debt
Where IVVD stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, IVVD finished 33.88% below its 150-day moving average ($1.21) and 47.02% below its 200-day moving average ($1.51). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IVVD overbought or oversold?
At the September 3, 2026 close, IVVD's RSI(14) was 59.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Invivyd, Inc. holds $160.1M in cash against $8.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$70.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -95.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Invivyd, Inc. and its sector.